Naloxone administration does not affect gonadotropin secretion in patients with Klinefelter's syndrome.
Plasma LH and FSH were measured every 20 min in a group of patients with Klinefelter's syndrome before and after placebo or naloxone administration (8 mg iv as a bolus followed by an infusion of 4 mg/h for 4 h) both in baseline conditions (N = 6) and during treatment with testosterone enanthate (200 mg im every two weeks; N = 4). The mean LH areas measured during saline infusion in baseline conditions (7888 +/- 758 IU/l per min mean +/- SEM) and during testosterone treatment (5042 +/- 2039 IU/l per min) were not significantly different from those measured during naloxone infusion (baseline 8317 +/- 818 IU/l per min; during testosterone treatment 5395 +/- 2007 IU/l per min). Similar results were obtained for FSH. These data suggest that in patients with Klinefelter's syndrome, the opioidergic inhibition of gonadotropin release is lacking and is not restored by testosterone replacement therapy.
D000328:Adult; D002986:Clinical Trials as Topic; D005640:Follicle Stimulating Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007262:Infusions, Intravenous; D007713:Klinefelter Syndrome / Q000097:blood / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D008297:Male; D009270:Naloxone / Q000008:administration & dosage*; D011897:Random Allocation; D012965:Sodium Chloride / Q000008:administration & dosage; D013739:Testosterone / Q000008:administration & dosage / Q000031:analogs & derivatives
D009270:Naloxone; D013739:Testosterone; D012965:Sodium Chloride; C004648:testosterone enanthate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone